Mustang Bio Stock Price, News & Analysis

Mustang Bio (NASDAQ: MBIO) announced encouraging interim data from a Phase 1/2 clinical trial of MB-106, a CD20-targeted CAR T cell therapy for high-risk B-cell non-Hodgkin lymphomas (B-NHL) and chronic lymphocytic leukemia (CLL). The trial showed a 93% overall response rate and a 67% complete response rate among 15 patients. The therapy demonstrated a favorable safety profile, with only 40% of patients experiencing cytokine release syndrome. Mustang aims to initiate a multicenter Phase 1/2 trial later in the year after FDA acceptance of their IND application.

Mustang Bio (NASDAQ: MBIO) will host a webinar on June 15, 2021, at 1:00 p.m. ET to discuss the MB-106 CD20-targeted CAR T cell therapy for high-risk B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. Dr. Mazyar Shadman from Fred Hutch will present interim results from the ongoing Phase 1/2 clinical trial. Mustang's management will also share details regarding the initiation of the trial after the FDA accepted its Investigational New Drug application. This presentation is scheduled ahead of the European Hematology Association 2021 Virtual Congress.

Mustang Bio has initiated a clinical trial at City of Hope for its MB-101 therapy targeting leptomeningeal brain tumors, including glioblastoma, ependymoma, and medulloblastoma. The trial involves 30 patients to assess safety and feasibility, with primary endpoints focusing on toxicity and three-month survival. Previous trials indicated promising results for MB-101 in treating this challenging cancer type. Mustang's leadership sees this as a significant milestone and aims to advance this potential treatment for patients dealing with these serious conditions.

Mustang Bio, Inc. (NASDAQ: MBIO) reported Q1 2021 financial results, highlighting significant clinical advancements. The FDA lifted a CMC hold on the MB-107 IND for infants with XSCID, enabling patient dosing soon. The company announced progress on MB-106, a CAR T cell therapy, with FDA approval to conduct a Phase 1/2 trial for B-NHL and CLL. As of March 31, 2021, cash equivalents totaled $130.4 million, up from $98.8 million at year-end 2020. Despite increased R&D and G&A expenses, the net loss was $15 million, or $0.19 per share.

Mustang Bio (NASDAQ: MBIO) announced that updated interim data from the Phase 1/2 clinical trial of MB-106, a CD20-targeted CAR T therapy, will be presented at the European Hematology Association 2021 Virtual Congress. The trial, conducted in collaboration with Fred Hutch, reported an overall response rate of 92% among 12 patients, with a complete response rate of 58%. Cytokine release syndrome occurred in 25% of patients, with manageable symptoms. The findings highlight the therapy's favorable safety profile compared to existing treatments.

Mustang Bio (NASDAQ: MBIO) announced the FDA's acceptance of its IND application for MB-106, a CAR T therapy targeting CD20 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. The Phase 1/2 multicenter trial is set to begin recruiting patients in Q3 2021. Previous studies indicated a favorable safety profile for MB-106, with an 89% overall response rate. With NHL and CLL accounting for significant cancer cases in the U.S., Mustang aims to provide effective treatment options for these patients.

Mustang Bio, a clinical-stage biopharmaceutical company (NASDAQ: MBIO), will participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit on April 26-27, 2021. CEO Manuel Litchman and CTO Knut Niss will be featured in a fireside chat on April 26 at 3:15 p.m. ET, with webcasts available on Mustang's website for 30 days post-event. The company focuses on cell and gene therapies for hematologic cancers and rare diseases, partnering with leading institutions to advance CAR T technologies.

Mustang Bio, Inc. (NASDAQ: MBIO) announced its financial results for the year ending December 31, 2020, highlighting robust progress in its cell and gene therapy programs. Notable achievements include MB-106 showing an 89% overall response rate and 44% complete response rate in B-cell non-Hodgkin lymphoma trials. Financially, Mustang reported cash reserves of $98.8 million, up from $62.4 million in 2019. Despite increased R&D expenses totaling $37.2 million, the net loss rose to $60 million, or $1.14 per share. Looking ahead, Mustang plans to advance multiple clinical trials in 2021, targeting innovative therapies for rare diseases.

Mustang Bio, Inc. (NASDAQ: MBIO) announced its management team's participation in three virtual investor conferences in March 2021. The events include:

• H.C. Wainwright Global Life Sciences Virtual Conference on March 9, 2021, available on-demand.
• Oppenheimer 31st Annual Virtual Healthcare Conference on March 16, 2021, with a fireside chat at 3:10 p.m. ET.
• Redburn Virtual Gene Therapy Summit on March 31, 2021, at 9:15 a.m. ET.

Webcasts will be accessible on Mustang's website for 30 days following each event.